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Abstract: Background: Dengue virus infection is a major public health problem. A hypothesis put forward for
severe dengue is the cytokine storm, a sudden increase in cytokines that induces vascular permeability. Previous
studies and our recent meta-analysis showed that IL-6, IL-8, IFNγ, TNFα, VEGF-A and VCAM-1 are associated
with dengue shock syndrome. Therefore, in this study we aim to validate the association of these cytokines with
severe dengue.
Methods & Findings: In a hospital based-case control study in Vietnam, children with dengue fever, other febrile
illness and healthy controls were recruited. Dengue virus infection was confirmed by several diagnostic tests.
Multiplex immunoassay using Luminex technology was used to measure cytokines simultaneously. A positive
association with dengue shock syndrome was found for VCAM-1, whereas a negative association was found for
IFNγ. Furthermore, multivariate logistic analysis also showed that VCAM-1 and IFNγ were independently
correlated with dengue shock syndrome.
Conclusion: IFNγ and VCAM-1 were associated with dengue shock syndrome, although their role in the severe
dengue pathogenesis remains unclear. Additional studies are required to shed further light on the function of these
cytokines in severe dengue.
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INTRODUCTION
Dengue virus infection is still a major public-health
burden in tropical and subtropical areas of the world, par-
ticularly in South-East Asia and the Western Pacific re-
gions. Annually, around 50 million dengue fever cases
occur worldwide, including more than 500,000 cases of se-
vere dengue [1, 2]. So far, there is no licensed antiviral
drug or vaccine available against dengue virus infection,
although some potential candidates are currently being
evaluated [3]. Dengue virus is a single-stranded RNA vi-
rus, composed of an isosahedral nucleocapsid that is coat-
ed by a lipid envelope and is transmitted by the Aedes
mosquito [2]. Four serotypes of the dengue virus exist, that
is DENV-1 to DENV-4 of the Flavivirus genus. Since in-
fection with one serotype does not provide protection
against the others, a secondary infection is more likely to
be severe [3].
Dengue virus infection can be diagnosed using cell
culture, serology, viral NS1 protein test or a PCR-based
method [1]. Dengue virus infection ranges from asympto-
matic or mild dengue fever (DF) to dengue hemorrhagic
fever (DHF) to dengue shock syndrome (DSS) according
to the 1997 World Health Organization (WHO) classifica-
tion [4]. DHF is characterized by increased vascular per-
meability, hemorrhagic manifestations, thrombocytopenia,
hepatomegaly and circulatory failure. DSS is defined by all
symptoms of DHF plus clinical evidence of shock, such as
narrow pulse pressure (< 20 mmHg), hypotension for age
and cold clammy skin [4]. Mortality in dengue virus infec-
tion is mostly due to the severe forms of the disease, espe-
cially DSS, with a case-fatality rate exceeding 5% in some
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Knowledge regarding the development of severe
forms of dengue virus infection is limited [6]. A popular
hypothesis on the pathogenesis of severe dengue is the oc-
currence of a “cytokine storm,” that is, alterations of cyto-
kine levels that can induce the malfunction of endothelial
cells [7]. Vascular permeability of endothelial cells will
consequently lead to the plasma leakage characteristic of
DHF and DSS. In a previous study, we discovered that
vascular endothelial growth factor A (VEGF-A) was sig-
nificantly increased in patients with severe dengue fever
[8]. Plasma levels of vascular cell adhesion molecule 1
(VCAM-1) are also reported to be significantly higher in
DHF than DF [9, 10]. Our recent meta-analysis also
showed that the cytokines interferon gamma (IFNγ),
interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor ne-
crosis factor alpha (TNFα) are associated with DSS, al-
though the number of studies upon which the conclusion
was based is small [11]. Because these six specific cyto-
kines show a positive association with DSS in particular,
we have chosen to further validate the relation of these cy-
tokines in the present study.
METHODS
Study design
This is a hospital-based case control study set in
Vietnam. Cases and controls were recruited in the Chil-
dren’s Hospital No. 2 in Ho Chi Minh City and the Center
for Preventive Medicine in Vinh Long Province.
Selection criteria and dengue classification
The inclusion criteria were: patients between 6
months and 15 years of age with suspected dengue virus
infection and hospitalization within the first five days of
illness. Exclusion criteria were: patients below 6 months or
above 15 years of age, hospitalization after five days of ill-
ness, and patients without confirmed diagnosis of dengue
infection. Patients with confirmed dengue fever were clas-
sified as cases. Patients with fever, but with negative sero-
logical, Real Time PCR and virological diagnosis for
dengue virus infection, were defined as having other non-
dengue febrile illness (OFI). A healthy control group was
used to serve as a baseline. The healthy control group was
recruited from school children living in Ho Chi Minh City
with negative dengue diagnostic test results and no symp-
toms of dengue or other diseases, between 3 and 10 years
of age. Sampling was performed upon study enrollment.
The hospital staff recorded the clinical symptoms of each
patient daily. Additionally, laboratory tests were performed
by the hospital staff as a daily routine. Sampling for cases
and OFI was performed upon enrollment in the hospital.
Sampling for controls was performed at enrollment in the
study. Data on full blood count were also collected. The
combined data were used to classify the dengue patients in
the categories DF, DHF and DSS according to the 1997
WHO guidelines [5]. According to the criteria, DF is an
acute fever with at least two of the following symptoms:
retro-orbital pain, myalgia, headache, leucopenia, rash and
hemorrhagic manifestations. DHF is characterized by acute
fever lasting 2 to 7 days and other symptoms such as
bleeding, thrombocytopenia (< 100,000 cells) or signs of
plasma leakage (hemoconcentration, ascites and pleural ef-
fusion). DSS manifests itself with signs of shock, such as
hypotension with cool and clammy skin, weak and rapid
pulse or a narrowing of the pulse pressure (< 20 mmHg).
In 2009, the WHO established new guidelines, separating
dengue cases into non-severe dengue and severe dengue
based on severe bleeding and/or severe organ impairment
[1]. In our study, however, the 1997 guidelines were still in
use at the time of sample collection in 2006 and 2007 and
classification was based upon the 1997 guidelines.
Ethical considerations
This study was approved by the institutional ethical
review committees of the Institute of Tropical Medicine,
Nagasaki University, and the Pasteur Institute in Ho Chi
Minh City. Written informed consent from parents and as-
sent from subjects was obtained by a study research nurse.
All biological materials collected were anonymized after
completion of demographic and clinical data collection.
Dengue diagnosis
Plasma samples for cytokine measurement were ob-
tained from dengue patients around the transition period of
fever to defervescence. The plasma was divided into two
tubes: one for dengue diagnostic testing and the other for
cytokine measurement. The plasma samples for cytokine
measurement were stored at −80°C. Several diagnostic
tests were performed to confirm dengue virus infection.
During the acute phase of the disease, blood was drawn
from patients to confirm dengue virus infection by virus
isolation or RNA detection with reverse transcription PCR.
Dengue virus isolation was performed using the C6/36 cell
line of Aedes albopictus and viral identification via immu-
nofluorescence with monoclonal antibodies supplied by
the Centers for Disease Control and Prevention (Fort
Collins, Colorado, USA) [12]. For the reverse transcription
PCR, a Ready-To-Go reverse transcriptase PCR kit
(Amersham, Massachusetts, USA) was used to detect the
dengue virus genome [13]. After the febrile period, when
the virus was no longer detectable in the blood, anti-
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dengue virus IgM and IgG antibodies were assessed by
ELISA (in-house kit of the Pasteur Institute, Ho Chi Minh
City, Vietnam) to confirm dengue virus infection. An
IgM/IgG ratio of < 1:8 indicated a secondary dengue infec-
tion [14]. For dengue serotype determination, reverse tran-
scription PCR and virus isolation were used [15].
Cytokine Measurement
Since a limited volume of blood was collected from
the children, we performed a multiplex immunoassay
using polystyrene beads based on Luminex technology.
The Procarta Immunoassay Kit—Polystyrene Beads
(Affymetrix, Santa Clara, California, USA) was used ac-
cording to the guidelines provided by the manufacturers.
The filter plate was read on the Luminex 100 instrument
(Luminex, Austin, Texas, USA).
Statistical Analysis
All data were stored in a computerized database (MS
Excel 2007, Microsoft, Redmond, Washington, USA). De-
scriptive and general statistics were calculated for all pa-
tients in the study. Skewness and kurtosis were tested to
assess normal distribution of the variables. For continuous
normally distributed variables, a one way ANOVA was
performed to compare multiple groups, while the groups
were assessed pair-wise using the Student’s t test. For non-
normal distributed variables, the Kruskal-Wallis test was
performed on all groups, whereas the Mann Whitney test
was used to compare groups head to head. The Chi-square
test was applied to categorical variables. Additionally, a
multiple logistic regression was performed. Finally, the
distribution of the cytokines was assessed for non-severe
versus severe dengue patients using the Mann Whitney test
for non-continuous variables and the Student’s t test for
continuous variables. Statistical significance was set at p <
0.05. All statistical tests were performed on the SPSS 20.0
(SPSS Inc., Chicago, Illinois, USA) statistical program.
RESULTS
Study population characteristics
The characteristics of the study population are sum-
marized in Table 1. A total of 67 patients were enrolled in
this study, including 5 healthy controls, 5 OFIs and 57
dengue patients. According to the 1997 WHO classifica-
tion, the 57 dengue patients were classified as 6 DF, 18
DHF and 33 DSS patients. No significant differences in
age or sex were found between the groups. Dengue sero-
type was comparable for all dengue patients. Dengue virus
4 was found to be completely lacking, and serotypes were
undetectable in 37 out of 57 cases. In total, 43 out of 57
dengue patients had a secondary DV infection, but no sig-
nificant differences were found among the groups. Hemat-
ocrit was significantly higher (p < 0.005) in the DSS group
compared to all the other groups and in the DHF group
compared to the OFI group. A significantly lower platelet
count was found (p < 0.049) in the DSS group compared to
the control and OFI groups. White blood cell count did not
differ among the groups.
The cytokines IL-6 and TNFα showed no significant
difference among groups. IL-8 was significantly higher (p
< 0.040) in the DSS group compared to the control group
and OFI groups and in the DHF group compared to the
control and DF groups. IFNγ levels were significantly de-
creased (p < 0.045) in the DSS group compared to the DF
group. VEGF-A was significantly higher in the DSS group
compared to the OFI group. Additionally, VCAM-1 levels
were significantly elevated (p < 0.045) in the DSS group
compared to the OFI and DF groups.
Cytokine levels of severe dengue versus non-severe
dengue
Univariate analysis was first carried out to differenti-
ate DSS from DHF and DF combined. The distribution of
the cytokine values is shown in Figure 1. The patients were
divided into a non-severe dengue group (DF and DHF
combined, n = 24) and a severe dengue group (DSS, n =
33). The levels of IL-6, IL-8, TNFα and VEGF-A did not
differ between the groups. However, we observed a signifi-
cantly higher level of VCAM-1 (p < 0.037) and a lower
level of IFNγ in the severe dengue group compared to the
non-severe dengue group.
To take the effects of all variables into account for the
association with DSS, a multivariate logistic regression
was carried out. After correction for age, sex, white blood
cell count (WBC) and the other cytokines, IFNγ (p < 0.04)
and VCAM-1 (p < 0.029) were significantly associated
with DSS (Table 2).
Primary infection versus secondary infection
The study participants were separated into groups
based on primary infection and secondary infection. The
results in Table 3 show that 14 patients had a primary
dengue virus infection, whereas 50 patients had a sec-
ondary infection. No significant difference in cytokine
level was found between the groups.
DISCUSSION
Six cytokines (IL-6, IL-8, VEGF-A, VCAM-1, TNFα
and IFNγ) were measured with the aim of validating their
association with dengue severity. Several cytokines were
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positively associated with DSS compared to the OFI or
control group, such as IL-8, VEGF-A and VCAM-1. For
IL-6 and TNFα, no differences were found among groups.
Interestingly, IFNγ was significantly decreased in DSS pa-
tients compared to DF patients. In the logistic regression
analysis, IFNγ showed a negative association with severe
dengue, both in the univariate and multivariate analysis. In
contrast, VCAM-1 had a positive association with DSS in
the univariate analysis and the adjusted analysis. We did
not find any significant difference between the groups for
cytokine levels of patients with primary dengue infection
and those with secondary dengue infection.
Cytokine IL-6 is secreted by T cells, macrophages,
NK cells and activated endothelial cells to stimulate innate
immune response. IL-6 is a potent mediator of fever and
acute phase reactions. Additionally, IL-6 facilitates the co-
agulation cascade together with other pro-inflammatory
cytokines. Some studies found increased levels of IL-6 in
severe dengue versus non-severe dengue, while others
failed to show this association [9, 16–19]. In our study, no
difference was found in IL-6 levels in any of the analyses.
IL-8 is a pro-inflammatory chemokine, which en-
hances vascular permeability and activates the innate im-
mune system. It is produced by monocytes, endothelial
cells and hepatocytes. Elevated levels of IL-8 have been
observed in DSS patients compared to non-shock dengue
Table 1. Clinical characteristics and laboratory parameters








N = 33 P value
Age (years) 5.6 ± 3.9 8.0 ± 4.6 9.8 ± 2.9 8.6 ± 3.2 8.6 ± 3.4 0.386
Female 3 (60%) 2 (40%) 3 (50%) 9 (50%) 17 (51%) 0.981
DV serotypes na na
 DV-1 1 (16.7%) 4 (22.2%) 3 (9.1%) 0.170
 DV-2 1(16.7%) 4 (22.2%) 2 (6.1%) —
 DV-3 1 (16.7%) 3 (16.7 %) 1 (3%) —
 DV-4 0 (0%) 0 (0%) 0 (0%)




 Primary 1 (16.7%) 4 (22.2%) 9 (27.3%) 0.623
 Secondary 5 (83.3%) 14 (77.8%) 24 (72.7%) —
HCT (%) 38.7 (34–44) 41.2 (37–43) 40.6 (38–46) 42.9 (37–45) 43.6 (37–53) < 0.005a,b,c,d,f
PLT (× 103) 94 (65–164) 126 (114–216) 119 (81–138) 70.7 (11–116) 43.5 (10–102) < 0.049a,b
WBC (× 103) 4.3 (2.3–4.5) 7.0 (2.3–7.6) 3.0 (2.1–5.6) 3.5 (1.2–10.5) 4.1 (0.7–10.4) 0.175
IL-6 1.25 (0.79–2.61) 0.70 (0.31–7.31) 1.26 (0–2.19) 1.20 (0–8.77) 1.33 (0–4.65) 0.864
IL-8 1.76 (0.7–2.65) 1.55 (0.73–4.69) 2.51 (1.93–4.08) 3.60 (0–12.80) 3.40 (1.38–18.11) < 0.040a,b,e,g
IFNγ 0.43 (0.23–3.26) 0.21 (0.14–30.73) 13.46 (0.34–
30.73)
1.38 (0–146.01) 0.53 (0.14–6.61) 0.045c
TNFα 3.03 (0–4.81) 1.94 (0.93–2.49) 1.65 (0.49–3.73) 1.74 (0.22–3.81) 1.35 (0–6.95) 0.687
VEGF-A 8.45 (3.42–13.22) 6.69 (2.92–13.42) 7.14 (3.91–16.38) 10.77 (0–29.01) 13.42 (3.42–72.65) 0.029b
VCAM-1 3444.0 ± 1300.1 2564.2 ± 1784.2 2785.2 ± 1514.5 3605.9 ± 1666.5 4159.7 ± 1045.5 < 0.045b,c
OFI, other febrile infections; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; DV, dengue virus;
HCT, hematocrit; PLT, platelets; WBC, white blood cells; IL-6, interleukine 6; IL-8, interleukine 8; IFNγ, interferon gamma; TNFα,
tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor; VCAM-1, vascular cell adhesion molecule 1. Cytokine
concentrations in pg/mL. One way ANOVA and student’s t test for continuous variables normally distributed, Kruskal-Wallis test
and Mann-Whitney test for continuous variables not-normally distributed, χ2 test for categorical variables.
Mean ± SD, number (percentage of total), median (minimum–maximum).
a between control and DSS patients
b between OFI and DSS patients
c between DF and DSS patients
d between DHF and DSS patients
e between control and DHF patients
f between OFI and DHF patients
g between DF and DHF patients
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patients and healthy controls [9, 20, 21]. Our findings con-
firm this association, as we found significantly higher lev-
Fig. 1. Cytokine levels between the groups: non-severe
dengue (DF/DHF) and severe dengue (DSS). The
Mann Whitney test was carried out to assess
differences of IL-6, IL-8, IFNγ, TNFα and VEGF-A
between the groups. Student’s t test was performed to
compare the levels of VCAM-1. Scatter plot graphs
with standard errors are shown.
els of IL-8 in the DSS and DHF groups compared to the
DF, OFI and control groups. IL-8 might be involved in se-
vere dengue pathogenesis, since dengue-infected endothe-
lial cells in vitro are observed to secrete IL-8 [22, 23].
Endothelial cells play a distinct role in the progression to
severe dengue, because the activation and cell death of
endothelial-cell lead to vascular permeability, plasma leak-
age and hemorrhage. Yet, it is difficult to establish the role
of IL-8 in severe dengue pathogenesis, since the evidence
of endothelial cells apoptosis in vivo is very limited [24].
Also, the fast recovery of DHF patients makes structural
damage to endothelial cells implausible.
IFNγ is mainly produced by T cells and NK cells. Its
main effects are monocyte and macrophage activation [25].
IFNγ has been associated with severe dengue [9, 26–28]. It
appears that IFNγ mostly peaks between the time of de-
clining viral load and the moment of defervescence and
plasma leakage, which indicates that the adaptive immuni-
ty has been activated. Activation of the adaptive immunity
can in turn enhance the cytokine production of NK cells,
leading to high levels of IFNγ in DF. Therefore it has been
proposed that high levels of IFNγ indicate recovery in DF.
In our study, IFNγ was particularly high in DF compared
to DSS, a finding consistent with previous studies [29–33].
Furthermore, IFNγ showed a negative association with se-
vere dengue in the multivariate logistic analysis.
VCAM-1 is an endothelial surface molecule ex-
pressed when endothelial cells are activated by cytokines
such as TNFα. VCAM-1 has been found at elevated levels
in DHF patients compared to DF patients and controls [10,
Table 2. Multivariate logistic regression model, DSS versus
non-shock cases (DF/DHF)
Parameter (n) Adjusted OR (95% CI) P value
Age 0.99 (0.76–1.30) 0.97
Sex 1.01 (0.24–4.23) 0.99
WBC (× 103) 1.00 (0.68–1.48) 0.99
IL-6 1.07 (0.40–2.89) 0.89
IL-8 0.83 (0.70–1.33) 0.83
IFNγ 0.63 (0.40–0.99) 0.043*
TNFα 1.12 (0.59–2.14) 0.73
VEGF-A 1.01 (0.93–1.12) 0.74
VCAM-1 1.00 (1.00–1.01) 0.029*
DSS, dengue shock syndrome; DF, dengue fever; DHF, dengue
hemorrhagic fever; OR, odds ratio; WBC, white blood cells;
IL-6, interleukine-6; IL-8, interleukine-8; IFNγ, interferon
gamma; TNFα, tumor necrosis factor alpha; VEGF-A, vascular
endothelial growth factor A; VCAM-1, vascular cell adhesion
molecule 1. Corrected for age, sex, WBC, IL-6, IL-8, IFNγ,
TNFα, VEGF-A and VCAM-1 in the adjusted OR.
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34, 35]. Our results are consistent, showing a significant
difference in VCAM-1 for the DSS group compared to the
OFI and DF groups. The distribution of VCAM-1 levels
between the non-severe and severe dengue group also
showed a significant increase. VCAM-1 mediates the ad-
hesion of lymphocytes and cells of the innate immune sys-
tem to the vascular endothelium to facilitate chemotaxis
[34]. Yet, it is unclear if VCAM-1 is the cause or result of
activated endothelium. Analysis of endothelial cell factors
may help to determine the role of VCAM-1 in severe
dengue pathogenesis.
TNFα has pro-inflammatory, vascular permeability-
enhancing and coagulation-activating effects. Elevated lev-
els of TNFα have been found in DHF compared to DF [9,
26, 27]. However, their role in the pathogenesis of DSS re-
mains unclear. It has been proposed that TNFα is secreted
by dengue virus-infected monocytes, which induce endo-
thelial cell production of reactive nitrogen and oxygen spe-
cies, leading to apoptotic cell death and therefore
hemorrhage [36, 37]. In our analysis, TNFα was not signif-
icantly different in the DSS group. Other studies have
shown that TNFα is particularly high in DSS patients dur-
ing defervescence [33]. But that could be due to different
sampling times, leading to lower levels of TNFα in DSS.
The low level of TNFα could furthermore be explained by
a possible difference in population or virus serotype.
VEGF-A is a cytokine that stimulates vasculogenesis
and angiogenesis. It effectively enhances vascular perme-
ability and also activates the coagulation system by upreg-
ulating the production of tissue factor [38, 39]. Recent
studies on dengue virus infection have reported elevated
levels of VEGF-A in DHF patients during the time of plas-
ma leakage [8, 40–42]. However, other studies produced
contradicting results, reporting lower levels of VEGF-A in
severe dengue patients [9, 43]. In our study, VEGF-A lev-
els were significantly elevated in DSS patients compared
to OFI patients, a finding consistent with most previous
studies.
Previous studies have shown that secondary dengue
infections carry a higher severity risk [6]. According to the
cytokine storm hypothesis, cytokine levels are assumed to
be elevated in a secondary dengue infection [7]. However,
no difference in cytokine levels between the primary and
secondary infection was found in our study, probably due
to the small sample size. Further studies are required to
clarify this hypothesis.
In this study, we collected plasma samples from chil-
dren infected with dengue virus in South Vietnam. The
children were carefully monitored and their symptoms and
laboratory results were recorded. Our sample therefore
consists of trustworthy data on DSS for children in
Vietnam. Since the plasma samples from the children were
only available in small amounts, we took advantage of
multiplex immunoassay technology to measure the cyto-
kines simultaneously. It appears that the cytokines IL-8,
IFNγ, VEGF-A and VCAM-1 are dengue-specific cyto-
kines, but it is difficult to hypothesize the exact role of
these cytokines for DSS. In the multivariate analysis, only
IFNγ and VCAM-1 were associated with severe dengue,
IFNγ showing a negative association. It is possible that
synergistic reactions between these cytokines occur, mak-
ing it harder to identify the contribution of each cytokine
to severe dengue pathogenesis [6, 44].
There were certain limitations in interpreting the re-
sults of cytokines, because several differences in cytokine
levels were observed between our study and other studies.
In this study, only a single plasma sample per patient was
used. Since the sampling time differs in each patient and
cytokine levels in dengue virus infection are reported to be
dynamic, this can result in differences. Since severe mani-
Table 3 Primary infection vs. secondary infection
Characteristics Primary Infection N = 14
Secondary Infection 
N = 50 P value
IL-6   1.59 (0–3.11)  1.13 (0–8.77) 0.137
IL-8   3.72 (0–8.03)  2.98 (0.19–18.11) 0.178
IFNγ   1.06 (0–30.73)  0.48 (0.14–146.01) 0.255
TNFα   1.03 (0–3.47)  1.70 (0–6.952) 0.066
VEGF-A  13.18 (0–24.12) 10.14 (2.92–72.65) 0.188
VCAM-1 3817.77 ± 1532.35 3728.73 ± 1400.61 0.717
OFI, other febrile infections; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; DV, dengue virus;
HCT, hematocrit; PLT, platelets; WBC, white blood cells; IL-6, interleukine 6; IL-8, interleukine 8; IFNγ, interferon gamma; TNFα,
tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor; VCAM-1, vascular cell adhesion molecule 1. Cytokine
concentrations in pg/mL. One way ANOVA and student’s t test for continuous variables normally distributed, Kruskal-Wallis test
and Mann-Whitney test for continuous variables not-normally distributed, χ2 test for categorical variables. Mean ± SD, number
(percentage of total), median (minimum–maximum).
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festations of dengue usually occur around the time of de-
fervescence, it is especially critical to take sampling time
into account. The ideal sampling time is immediately after
the onset of the disease, but most patients are hospitalized
after a few days of illness. Another limitation in our study
involved the low number of participants in the control, OFI
and DF groups. Since our study was a case control study
and we primarily focused on the DSS compared to the
DHF group, we used the remaining DF samples. Thus, the
non-significant associations between DF and DHF/DSS
should be interpreted with caution. Finally, a large number
of patients is necessary to find significant differences in
cytokine level, since cytokines are only present in plasma
in very small amounts. A good setting would be a large
prospective study in which blood samples are drawn from
the patients every day of illness. Additional research needs
to be done to shed further light on the role of cytokines in
severe dengue pathogenesis.
In conclusion, IFNγ and VCAM-1 were associated
with dengue shock syndrome, while TNFα, IL-6, IL-8, and
VEGF-A were not. Additional large prospective studies
are required to further investigate the function of these cy-
tokines in severe dengue.
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